ナノボディ療法は,NMDA受容体の機能低下を救済する
Mathieu Oosterlaken1, Angelina Rogliardo1,2, Tatiana Lipina3
1Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, Montpellier, France.
Nature
|July 23, 2025
まとめ
研究者らは新しいナノボディ療法を開発し 脳の受容体を成功裏に標的とし マウスモデルにおける認知欠陥を修正しました 精神病や神経変性疾患の治療に 新しい希望の扉が開けています
科学分野:
- 神経科学
- 免疫療法
- 薬物開発
背景:
- 精神病や神経変性疾患は 新しい治療法が必要です
- 伝統的な免疫療法では 脳への浸透は困難です
- カメリッド重鎖抗体 (ナノボディ) は,脳を標的とする可能性がある.
研究 の 目的:
- 脳の受容体を標的とする二価のバイパロピクナノボディを開発し評価する.
- 認知障害に対する ナノボディの治療の可能性を評価する.
- 脳の障害を治療するための 実行可能な戦略としてナノボディを確立する
主な方法:
- 2つのカメリッド重鎖ナノボディを用いた二価バイパロピック抗体の開発.
- 1つのナノボディはメタボトロピー性グルタミン酸受容体2に結合し,もう1つはその活性を増強する.
- 臨床前のマウスモデルにおいて,ナノボディを周辺的に投与する.
主要な成果:
- バイバルナノボディは 外周投与後に脳に到達しました
- NMDA受容体の機能低下のマウスモデルにおける認知障害は修正された.
- 治療効果は,単発注射後少なくとも7日間持続し,サブ慢性的な治療で維持された.
結論:
- ナノボディは 治療目的で脳の受容体を 効果的に標的にすることができます
- この研究は,ナノボディベースの脳療法の概念の証明を提供します.
- この発見は精神病や神経変性疾患などの 脳疾患の治療に 新たな可能性をもたらします
関連する概念動画
01:19Ligand-gated Ion Channels
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...